- •71% of studies reported a negative impact of RRBSO on sexual function.
- •RRBSO has a statistically significant negative impact on sexual function (p = 0.03).
- •Vaginal dryness increases significantly post-RRBSO (p < 0.00001).
- •Sexual function deteriorates post RRBSO irrespective of menopausal status.
- •The effect of RRBSO on sexual function cannot be fully reversed by HRT.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Obstetrics and Gynecology and Reproductive Biology
United States Cancer Statistics Working Group (2014). United States Cancer Statistics 1999-2011 Incidence and Mortality Web-based Report. Atlanta, USA, 2014. www.cdc.gov/cancer/uscs. [accessed 17/2/21].
- The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy.Maturitas. 2016; 85: 42-48https://doi.org/10.1016/j.maturitas.2015.12.004
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies.Am J Hum Genet. 2003; 72: 1117-1130https://doi.org/10.1086/375033
- Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2.Science. 2003; 302: 643-646https://doi.org/10.1126/science.1088759
- Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021. NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2021; 1: 77-102https://doi.org/10.6004/jnccn.2021.0001
- The Hereditary Ovarian Cancer Clinical Study Group. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.Gynecol Oncol. 2018; 150: 85-91https://doi.org/10.1016/j.ygyno.2018.05.011
- Cancer Risks for PMS2 -Associated Lynch Syndrome.J Clin Oncol. 2018; 36: 2961-2968https://doi.org/10.1200/JCO.2018. 78.4777
- Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database.Genet Med. 2020; 22: 15-25https://doi.org/10.1038/s41436-019-0596-9
- Impact of risk-reducing salpingo-oophorectomy in premenopausal women.Climacteric. 2017; 20: 212-221https://doi.org/10.1080/13697137.2017.1285879
- Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.Eur J Cancer. 2017; 84: 159-167https://doi.org/10.1016/j.ejca.2017.07.018
- Characteristics of Lynch syndrome associated ovarian cancer.Gynecol Oncol. 2018; 150: 324-330https://doi.org/10.1016/j.ygyno.2018.03.060
- Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study.Int J Gynecol Cancer Supplement. 2006; 16: 54-59
- Screening for Familial Ovarian Cancer: Failure of Current Protocols to Detect Ovarian Cancer at an Early Stage According to the International Federation of Gynecology and Obstetrics System.J Clin Oncol. 2005; 23: 5588-5596https://doi.org/10.1200/JCO.2005.05.097
- Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy.Gynecol Oncol. 2016; 140: 101-106https://doi.org/10.1016/j.ygyno.2015.11.016
- Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk mortality.JAMA. 2010; : 967-975https://doi.org/10.1001/jama.2010.1237
- Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations.N Engl J Med. 2002; 346: 1616-1622https://doi.org/10.1056/NEJMoa012158
- Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation.J Clin Oncol. 2014; 32: 1547-1553https://doi.org/10.1200/JCO.2013.53.2820
- Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study.J Clin Oncol. 2008; 26: 1331-1337https://doi.org/10.1200/JCO.2007.13.9626
- Predictors of Prophylactic Bilateral Salpingo-Oophorectomy Compared With Gynecologic Screening Use in BRCA1/2 Mutation Carriers.J Clin Oncol. 2007; 25: 301-307https://doi.org/10.1200/JCO.2006.07.4922
- Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.Gynecol Oncol. 2019; 152: 145-150https://doi.org/10.1016/j.ygyno.2018.10.040
- Exploring factors that impact uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO) in high-risk women.Menopause. 2020; 27: 26-32https://doi.org/10.1097/gme.0000000000001422
American Psychiatric Association. Sexual Dysfunction. Diagnostic and Statistical Manual of Mental Disorders (5th ed) 2013. https://dsm.psychiatryonline.org. [accessed 17/2/21].
- Unraveling the Next Chapter: Sexual development, body image, and sexual functioning in female BRCA carriers.Cancer J. 2009; 15: 15-18https://doi.org/10.1097/ppo.0b013e31819585f1
- Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy.Gynecol Oncol. 2016; 140: 95-100https://doi.org/10.1016/j.ygyno.2015.11.002
- Addressing Sexual Dysfunction After Risk-Reducing Salpingo-Oophorectomy: Effects of a Brief, Psychosexual Intervention.J Sex Medicine. 2015; 12: 189-197https://doi.org/10.1111/jsm.12713
- What I wish I’d known before surgery: BRCA carriers’ perspectives after bilateral salipingo-oophorectomy.Fam Cancer. 2011; 10: 79-85https://doi.org/10.1007/s10689-010-9384-z
- kConFab Psychosocial Group on behalf of the kConFab Investigators. Looking different, feeling different: women’s reactions to risk-reducing breast and ovarian surgery.Fam Cancer. 2012; 11: 215-224https://doi.org/10.1007/s10689-011-9504-4
- Review Article: Sexuality and Risk-Reducing Salpingo-oophorectomy.Int J Gynecol Cancer. 2017; 27: 847-852https://doi.org/10.1097/IGC.0000000000000943
- Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review.Maturitas. 2011; 70: 261-265https://doi.org/10.1016/j.maturitas.2011.08.001
- Meta-analysis of observational studies in epidemiology.A proposal for reporting. JAMA. 2019; 15: 2008-2012https://doi.org/10.1001/jama.283.15.2008
- The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement.PLoS Med. 2009; 6: e1000097https://doi.org/10.1371/journal.pmed.1000097
- The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.Ottawa Hospital Res Inst. 2019;
- Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy.Climacteric. 2009; 12: 404-409https://doi.org/10.1080/13697130902780846
- Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy.Menopause. 2019; 26: 132-139https://doi.org/10.1097/gme.0000000000001176
- Quality of life in BRCA1 and BRCA2 mutation carriers (B1/2) following risk-reducing salpingo-oophorectomy (RRS0). American Society of.Clin Oncol. 2014; 35
- Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer.Fam Cancer. 2001; 1: 149-156https://doi.org/10.1023/a:1021119405814
- A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer.Gynecol Oncol. 2009; 112: 594-600https://doi.org/10.1016/j.ygyno.2008.11.039
- Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer.Psycho Oncol. 2001; 10: 231-241https://doi.org/10.1002/(ISSN)1099-161110.1002/pon.v10:310.1002/pon.512
- Long-term outcomes of risk-reducing surgery in unaffected women at increased familial risk of breast and/or ovarian cancer.Fam Cancer. 2015; 14: 105-115https://doi.org/10.1007/s10689-014-9759-7
- Quality of life after risk-reducing salpingo-oophorectomy in BRCA carrier.Ann Oncol. 2016; https://doi.org/10.1093/annonc/mdw575
- Relationship satisfaction predicts sexual activity following risk-reducing salpingo-oophorectomy.J Psychosom Obst Gyn. 2014; 35: 62-68https://doi.org/10.3109/0167482X.2014.899577
- Quality-of-Life Effects of Prophylactic Salpingo-Oophorectomy Versus Gynecologic Screening Among Women at Increased Risk of Hereditary Ovarian Cancer.J Clin Oncol. 2005; 23: 6890-6898https://doi.org/10.1200/JCO.2005.02.626
- The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause.Fam Cancer. 2012; 11: 403-410https://doi.org/10.1007/s10689-012-9527-5
- Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations.Psycho Oncol. 2020; 29: 331-338https://doi.org/10.1002/pon.v29.210.1002/pon.5253
- Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy.Gynecol Oncol. 2003; 89: 281-287https://doi.org/10.1016/S0090-8258(03)00072-6
- Factors Associated with Altered Long-Term Well-Being After Prophylactic Salpingo-Oophorectomy Among Women at Increased Hereditary Risk for Breast and Ovarian Cancer.Oncol. 2011; 16: 1250-1257https://doi.org/10.1634/theoncologist.2010-0336
- Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma.Cancer. 2011; 117: 2659-2667https://doi.org/10.1002/cncr.25820
- Hysterectomy and Sexual Functioning.Jama. 1999; 282: 1934-1941https://doi.org/10.1001/jama.282.20.1934
- Body image and sexual problems in young women with breast cancer.Psycho Oncol. 2006; 15: 579-594https://doi.org/10.1002/(ISSN)1099-161110.1002/pon.v15:710.1002/pon.991
- Sexual Function after Breast Cancer.J Sex Med. 2011; 8: 294-302https://doi.org/10.1111/j.1743-6109.2010.02034.x
- Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction.Eur J Cancer. 2000; 36: 1938-1943https://doi.org/10.1016/S0959-8049(00)00197-0
- Quality of life and patient satisfaction in breast cancer patients after immediate breast reconstruction: a prospective study.Breast. 2005; 14: 201-208https://doi.org/10.1016/j.breast.2004.10.008
- Hormonal dynamics associated with the menopause.Clin Obstet Gynecol. 1976; 19: 775-788
- Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause.Gynecol Oncol. 1991; 1: 42-45
- The Impact of Hormone Replacement Therapy on Menopausal Symptoms in Younger High-Risk Women After Prophylactic Salpingo-Oophorectomy.J Clin Oncol. 2006; 24: 3576-3582https://doi.org/10.1200/JCO.2005.05.1896
National Institute for Health and Care Excellence (NICE). Menopause: diagnosis and management. NICE guidelines 2019. https://www.nice.org.uk/guidance/ng23. [accessed 1/8/21].
- Estrogen and Androgen Hormone Therapy and Well-Being in Surgically Postmenopausal Women.J Women’s Health. 2006; 15: 898-908https://doi.org/10.1089/jwh.2006.15.898
- Transdermal Testosterone Treatment in Women with Impaired Sexual Function after Oophorectomy.New Engl J Medicine. 2000; 343: 682-688https://doi.org/10.1056/NEJM200009073431002
- Influence of Estrogen Plus Testosterone Supplementation on Breast Cancer.Arch Intern Med. 2009; 169: 41https://doi.org/10.1001/archinternmed.2008.507
- Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.Gynecol Oncol. 2019; 153: 192-200https://doi.org/10.1016/j.ygyno.2018.12.014
- Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group.J Clin Oncol. 2005; 23: 7804-7810https://doi.org/10.1200/JCO.2004.00.8151
- The Hereditary Breast Cancer Clinical Study Group. Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers.J National Cancer Inst. 2008; 100: 1361-1367https://doi.org/10.1093/jnci/djn313
- The Hereditary Breast Cancer Clinical Study Group. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1.Oncol. 2018; 4: 1059https://doi.org/10.1001/jamaoncol.2018.0211
Royal College of Obstetricians & Gynaecologists (RCOG). Alternatives to HRT for the Management of Symptoms of the Menopause. Scientific Impact Paper No. 6. 2010. https://www/rcog.org.uk/globalassets/documents/guidelines/scientific-impact-papers/sip_6.pdf. [accessed 1/8/21].
- Mindfulness-Based Stress Reduction (MBSR) or Psychoeducation for the Reduction of Menopausal Symptoms: A Randomized, Controlled Clinical Trial.Sci Rep UK. 2018; 8https://doi.org/10.1038/s41598-018-24945-4
- Discussing Sexuality With Women Considering Risk-Reducing Salpingo-oophorectomy.Int J Gynecol Cancer. 2016; 26: 1338-1344https://doi.org/10.1097/igc.0000000000000750
- Risk-Reducing Bilateral Salpingo-Oophorectomy and Sexual Health: A Qualitative Study.J Obstetrics Gynaecol Can. 2012; 34: 172-178https://doi.org/10.1016/S1701-2163(16)35160-X
- The Impact of vaginal laser treatment for genitourinary syndrome of menopause in breast cancer survivors: A systematic review and meta-analysis.Clin Breast Cancer. 2019; 19: e556-e562https://doi.org/10.1016/j.clbc.2019.04.007
Royal College of Obstetricians & Gynaecologists (RCOG). The Distal Fallopian Tube as the Origin of Non-Uterine Pelvic High-Grade Serous Carcinomas. Scientific Impact Paper No. 44. 2014. https://www.rcog.org.uk/globalassets/documents/guidelines/scientific-impact-papers/sip44hgscs.pdf. [accessed 17/2/21].